Groupe Hospitalier Universitaire Paris Psychiatrie Et Neuroscience

The Institut de Neuromodulation is conducting studies that explore innovative therapies for acute ischemic stroke, aiming to improve functional recovery and quality of life.

• Acute ischemic stroke
• Aneurysmal subarachnoid hemorrhage
• Traumatic brain injury
• Intracerebral hemorrhage
• Diffuse intrinsic pontine glioma

These efforts at Groupe Hospitalier Universitaire Paris Psychiatrie Et Neuroscience reflect a commitment to advancing neurocritical care.

Clinical research focuses on novel interventions for major depressive disorder and treatment‑resistant forms, seeking faster symptom relief.

• Major Depressive Disorder
• Treatment‑Resistant Depression
• Generalized Anxiety Disorder
• Ultra High Risk of Psychosis
• Treatment‑Resistant Schizophrenia

The site’s multidisciplinary team integrates psychiatry and neuromodulation to enhance mental health outcomes.

Trials evaluate strategies to prevent secondary events after ischemic stroke and to optimize anticoagulation in patients with vascular pathology.

• Ischemic stroke
• Large vessel occlusion stroke
• Aneurysmal subarachnoid hemorrhage
• Anticoagulation after intracerebral hemorrhage
• Endovascular coiling of unruptured aneurysms

Research at Groupe Hospitalier Universitaire Paris Psychiatrie Et Neuroscience aims to reduce mortality and disability from vascular disorders.

Investigators are testing immunomodulatory approaches for myasthenia gravis and sickle cell disease, targeting disease progression and organ protection.

• Myasthenia gravis
• Sickle cell disease
• Hospital‑acquired pneumonia
• Sepsis in ICU
• Immune‑mediated neuroinflammation in Alzheimer disease

The institute leverages its expertise in neuromodulation to modulate immune pathways for better patient outcomes.

Oncologic studies address aggressive brain tumors such as diffuse intrinsic pontine glioma, testing targeted agents combined with radiotherapy.

• Diffuse intrinsic pontine glioma
• Other diffuse midline gliomas
• Brain arteriovenous malformations
• Glioma
• High‑grade pediatric brain tumors

Through collaborations, the site strives to bring precision medicine to patients with rare central nervous system cancers.